-+ 0.00%
-+ 0.00%
-+ 0.00%

Luye Pharma's Ruoxinlin Wins China Approval for Generalized Anxiety Disorder

PUBT·11/19/2026 11:32:19
Listen to the news
Luye Pharma's Ruoxinlin Wins China Approval for Generalized Anxiety Disorder
  • China's National Medical Products Administration approved Luye Pharma's Ruoxinlin for generalized anxiety disorder, its second indication in China.
  • The drug was first approved in China in November 2022 for major depressive disorder.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261119-12419003), on November 19, 2026, and is solely responsible for the information contained therein.